MUMBAI, March 8- Indian drugmaker Ranbaxy Laboratories Ltd, reeling under a flurry of regulatory rebukes due to poor quality, has recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after doseage mix-up was detected.» Read More
A cancer vaccine more than doubled the survival time of people with the most common and deadly type of brain tumor, U.S. researchers said.
China Telecom and its state parent will pay more than $14 billion to buy a wireless network owned by the China Unicom group, entering a lucrative mobile arena in the first deal reached under Beijing's sweeping overhaul of the world's largest telecoms industry.
A former Credit Suisse investment banker convicted of leaking inside information about pending mergers was sentenced to 10 years in prison by a federal judge Friday.
John F. Marshall spent decades teaching at business schools and watching his students parlay his lessons into fortunes on Wall Street. But when he and another professor reached for some of those riches themselves, events took a startling turn, the authorities say.
Bear Stearns plans to turn over documents to securities regulators showing that financial giants like Goldman Sachs Group, Citadel Investment Group and Paulson & Co cut their exposure to the securities firm before its collapse, the Wall Street Journal reported on Wednesday.
China will issue three Licenses for high-speed third-generation mobile phone services and called for a merger of China Unicom and China Netcom, two of its four biggest telecoms providers, in a long-awaited industry revamp.
New data on Pfizer's Chantix drug to help stop smoking raises new concerns about serious side effects, especially for drivers, pilots and others operating heavy machinery, researchers said on Wednesday.
The White House said that President Bush would not veto a final bill from Congress that orders a halt to filling the Strategic Petroleum Reserve while oil prices are very high.
Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial for a heart stent is aimed at "millions of people who are ill-equipped to make judgments" about the device.
One of the hedge fund industry's most successful asset managers is calling for more regulatory scrutiny of Wall Street.
JPMorgan, acquiring rival investment bank Bear Stearns amid one of the worst market slumps ever, so far has extended jobs to about 6,000 out of Bear's nearly 14,000 employees, a person familiar with the situation said on Monday.
New York Insurance Superintendent Eric Dinallo said it may make sense to discuss regulating certain segments of the credit derivatives market as if they were insurance products.
Merck, whose earnings have been hurt by patent expirations and declining sales of its Vytorin cholesterol fighter, said Monday it will eliminate another 1,200 members of its U.S. sales force as part of a restructuring begun in late 2005.
Federal prosecutors in New York have formed a task force together with other government agencies to examine the collapse of the market for risky home loans, a spokesman for the U.S. Attorney's Office in Brooklyn said Monday.
The Federal Reserve on Friday joined other U.S. banking regulators in backing new limits on certain billing practices by credit card companies.
Merck says it has received a warning letter from the Food and Drug Administration over concerns at one of its major vaccine manufacturing plants.
Genentech and Biogen Idec said a key study of Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.
U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.
U.S. securities regulators said on Thursday they filed a settled complaint against a Wall Street trader accused of intentionally spreading false rumors about the planned acquisition of Alliance Data Systems while selling the stock short.
Many companies are guilty of "greenwashing" -- claims that mislead consumers, by words or image, about the environmenal impact of their products, experts say.